Purpose: Dropped head syndrome is characterized by a gradual forward sagging of the head due to the isolated weakness of the neck extensor muscles. The syndrome has a relatively benign clinical course. To date, there have been no reports of dropped head syndrome in epileptic patients. Methods: Nine patients with intractable epilepsy (mean age, 33.6 AE 9.91 years), each presenting with apparent dropped head, were evaluated. The duration of the drooping head symptom varied from 3 to 15 years (mean, 7.4 AE 4.06 years), with a slowly progressing weakness in most of the patients. In all of the patients, extensive clinical, laboratory, electrophysiological, histopathological, and neuroimaging examinations were performed. Results: The weakness in all of the subjects was strictly limited to the cervical paraspinal muscles. Laboratory studies produced normal results from all subjects. EMG and muscle biopsy were normal or revealed subtle nonspecific myopathic changes without inflammation in the cervical paraspinal muscles. Polymyographic investigation revealed that none of the patients had convincing dystonic spasms of the anterior neck muscles. No atrophy or fatty changes of the neck extensor muscles were observed on CT or MRI. In most of the patients (7/9), altered L-carnitine concentrations were observed (four patients displayed a marked decrease in plasma carnitine concentrations, and three other patients showed abnormalities in urinary excretion of carnitine). Conclusions: These findings seem to suggest that a secondary carnitine deficiency, induced by antiepileptic drugs (principally valproic acid), represents a plausible pathogenetic mechanism for the development of dropped head in some epileptic patients.
Introduction
Noninflammatory myopathy, affecting predominantly the neck extensors, has been described by Suarez and Kelly as a dropped head syndrome. 1 It is characterized by a gradual forward sagging of the head due to the isolated weakness of the neck extensor muscles. The syndrome has a relatively benign clinical course, with the complaints having a slowly progressive character in some of the subjects. This condition may be difficult to distinguish from more ominous neuromuscular disorders that present with severe neck extensor weakness, including myasthenia gravis, motor neuron disease, and inflammatory axial myopathy. It could be associated with a variety of pathologies, including spine disorders, parkinsonism, dystonias, and hyperparathyroidism. [2] [3] [4] [5] [6] [7] To date, there have been no reports of dropped head syndrome in epileptic patients.
Methods
Nine patients with intractable epilepsy (six males, three females; ranged in age from 20 to 49 years, with a mean age of 33.6 AE 9.91 years), each presenting with apparent dropped head syndrome, were included in the study. Eight of the subjects suffered from refractory multifocal epilepsy; the remaining subject was diagnosed with an intractable progressive myoclonic epilepsy of unknown etiology. All patients were mildly to severely mentally retarded, with IQ ranged from 34 to 70 (mean, 58.7 AE 11.87) on the Wechsler Adult Intelligence Scale (WAIS-R). Despite intensive pharmacological polytherapy (combination of two to three antiepileptic drugs) and therapeutic vagal nerve stimulation (in four of the subjects), the seizure frequency in our patients ranged from 4 to 85 seizures per month (mean, 32.6 AE 29.92). None of our patients were taking neuroleptic drugs at the time of our investigation, nor had they ever taken neuroleptic drugs. The clinical features are summarized in Table 1 . The duration of the drooping head symptom varied from 3 to 15 years (mean, 7.4 AE 4.06 years), and the weakness was slowly progressive in most of the patients. In all of the patients, extensive clinical, laboratory (including blood and urine tests for L-carnitine, lactate, pyruvate, amino acids, and organic acids), electrophysiological (polymyography and EMG from the splenius capitis and sternocleidomastoid muscles), histopathological (biopsy specimens from the splenius capitis and vastus lateralis muscles, including histochemical stains for NADH, SDH, ATPase pH 9.4, pH 4.6, and pH 4.3, Oil-red-O, Acid phosphatase, PAS, and Esterase), and neuroimaging examinations (MRI or CT scans of the brain and paraspinal muscles) were performed.
Results
In all of the subjects, the weakness was strictly limited to the cervical paraspinal muscles. No weakness in other muscle groups, including in the shoulder girdle region, was found. Due to the weakness of the neck extensor muscles, our patients were unable to hold the head upright, although on request they could voluntarily and temporarily overcome the problem and straighten the head up. However, after a few seconds or minutes the gradual forward sagging of the head could be observed. The range of neck flexion varied roughly from 308 in the milder cases to 608 in the most severe cases (Fig. 1) . The weakness did not fluctuate during the day. Laboratory studies, including serum electrolytes and creatine-kinase, produced normal results in all subjects, and antibodies against acetylcholine receptors were not detected. Thyroid function was normal in most of the patients; in three of them, slight, clinically non-significant changes were found. EMG study and muscle biopsy were normal or revealed subtle nonspecific myopathic changes without inflammation in the cervical paraspinal muscles. Electrophysiological and histopathological examinations of control muscles revealed no abnormities. Neither histological nor biochemical findings suggestive of mitochondrial disorders were observed. Polymyographic investigation revealed that none of the patients had convincing dystonic spasms of the anterior neck muscles. No atrophy or fatty changes of the neck extensor muscles were observed on CT or MRI. In one patient, slight symmetric edema-like changes in the neck muscles were observed in a CT scan (pt. 6). In most of our patients (7/9), altered L-carnitine concentrations were observed (four patients displayed a marked decrease in plasma carnitine concentrations, and three patients showed abnormalities in urinary excretion of the carnitine with normal plasma level values) ( Table 2) . No obvious correlations between the degree of carnitine deficiency and the neck extensor weakness were revealed.
Discussion
The nine patients with severe intractable epilepsies and mental retardation reported in this study manifested an unusual phenomenon of marked anterior curvature of the cervical spine, designated as dropped head syndrome. To the best of our knowl- LGS: Lennox-Gastaut syndrome; PME: progressive myoclonic epilepsy; VNS: vagal nerve stimulation. edge, this is the first description of dropped head syndrome in epileptic patients. The extensive examination of our patients obviously excluded known neuromuscular disorders that present with severe neck extensor weakness, including myasthenia gravis, motor neuron disease, and inflammatory axial myopathy. There were no clear-cut myopathic changes in the EMG or histopathological studies on the paraspinal muscles that would permit speculation about idiopathic non-inflammatory axial myopathy as the crucial pathogenetic mechanism of development of dropped head syndrome in our patients. Instead, in most of our patients, alterations of L-carnitine concentrations were observed (a significant decrease of the total and/or unbound carnitine plasma levels in four subjects, and a significant increase in urine acylcarnitine/unbound carnitine ratio in an additional three subjects). LCarnitine, the active isoform of carnitine, is an essential cofactor in the b-oxidation of fatty acids. Its main function is transporting long-chain fatty acids into the mitochondrial matrix for beta-oxidation to provide cellular energy. 8 The main consequence of carnitine deficiency is an impaired energy metabolism, which may be accompanied by a moderate degree of muscular dysfunction (causing weakness). Carnitine deficiency may be primary or secondary, resulting from inborn errors of metabolism, reduced dietary intake, medical conditions, and treatment with multiple antiepileptic drugs, including phenobarbital, phenytoin, carbamazepine, and especially valproic acid. 9, 10 It is noteworthy that five of our patients were taking high doses of valproates at the time of the study, and all of them had been medicated with valproate at some point. Additionally, all subjects were medicated with other antiepileptic drugs (AEDs), which demonstrate the obvious potential to provoke secondary carnitine deficiency. It is, therefore, not surprising that carnitine deficiency (or abnormal urinary carnitine excretion, possibly reflecting a higher demand for carnitine in the organism) was observed in a large portion of our subjects. The crucial point is whether secondary carnitine deficiency truly can be considered as the main pathogenetic factor in the development of dropped head syndrome in epileptic patients. Karpati et al. and VanDyke et al. described weak neck muscles (extensors and flexors) and proximal limbs as prominent features in carnitine deficiency in young boys. 9, 11 In addition, carnitine deficiency was repeatedly described as the cause of camptocormia (bent spine syndrome), which is a disorder characterized by extreme flexion of the thoracolumbar spine. It has been suggested that dropped head syndrome and camptocormia could be viewed as two different manifestations of the same axial myopathy. 12 It is worth noting that camptocormia was described in a mentally retarded 23-year-old woman with myoclonic astatic epilepsy as an obvious adverse effect of valproate monotherapy by Kiuru and Iivanainen. 13 It may be that dropped head syndrome in epileptic patients does not represent a homogeneous entity. We did not have abnormal carnitine metabolism findings in all of our patients. However, the crucial carnitine level in muscles does not necessarily correspond to its plasma levels. A depletion of carnitine level can occur in muscle tissue despite normal serum and urine carnitine concentrations. Unfortunately, for technical reasons we were unable to verify the presumed carnitine deficiency in the neck muscles of our patients. The pathogenesis of dropped head in our cases thus remains hypothetical. It can be nevertheless suggested that a secondary carnitine deficiency induced by antiepileptic drugs (principally by valproic acid) represents a plausible pathogenetic mechanism for the development of dropped head syndrome in some epileptic patients.
From a clinical point of view, it is very important that the dropped head syndrome not be perceived as a rarity throughout the epileptic community. It can be overlooked and undiagnosed because of its predominant occurrence in desperate patients. The drooping head can nevertheless significantly worsen the patients' quality of life. Further evaluations are needed to determine the actual prevalence of dropped head syndrome in patients with epilepsy, and whether drooping head in these subjects is a consequence of intensive antiepileptic drug treatment leading to secondary carnitine deficiency. If this is the case, a replacement of AEDs or carnitine supplementation should be considered. 14 
